{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:00:08Z","timestamp":1780902008617,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute to Memorial Sloan Kettering Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clomiphene citrate (CC) is an established treatment for men with low testosterone, but predictors of treatment response remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To identify factors associated with clinically meaningful increases in serum testosterone levels during CC therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed men diagnosed with low testosterone and treated with CC. Inclusion criteria were (1) a diagnosis of low testosterone (total testosterone (TT) \u2264300\u00a0ng\/dL with symptoms) or borderline low testosterone (TT 300-400\u00a0ng\/dL with objective signs of low testosterone (low bone density or elevated HbA1c)), (2) laboratory follow-up within 12-weeks of initiation, and (4) no prior testosterone therapy. Initial CC dosing was 25\u00a0mg every other day (QOD), with escalation to 50\u00a0mg QOD if TT remained &amp;lt;400\u00a0ng\/dL. Labs were redrawn every 4-weeks following dose changes until TT was at goal or until CC discontinuation. Discontinuation within 12-weeks without documented response constituted treatment failure. TT was assessed using liquid chromatography-mass spectrometry. Multivariable models were used to identify predictors of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The primary outcome was achievement of treatment response, defined as TT \u2265400\u00a0ng\/dL on treatment plus an increase in TT \u2265200\u00a0ng\/dL from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 292 men with median age of 60 (IQR 50, 66) years, median baseline TT (219, 314) 264\u00a0ng\/dL, and median baseline luteinizing hormone (LH) of 3.5 (2.6, 5.1) mIU\/mL. Comorbidities included diabetes (18%), hyperlipidemia (46%), hypertension (44%), prior radical prostatectomy (41%), prostate radiotherapy (12%), and androgen deprivation therapy (ADT) (4.5%). Treatment response was achieved in 136 of 292 (47%) patients; 156 (53%) failed to meet response criteria within 12-weeks. Multivariable analysis identified baseline LH (increase per mIU\/mL) (OR 0.82, CI = 0.71-0.95, P\u00a0=\u2009.008) as a significant negative predictor for achieving treatment response. Likewise, prior ADT was predictive for poor response (OR 0.11, CI = 0.01-0.6, P\u00a0=\u2009.039). Baseline TT and age at start of CC treatment were not predictive. The study included 292 men with median age of 60 (IQR 50, 66) years, median baseline TT (219, 314) 264\u00a0ng\/dL, and median baseline LH of 3.5 (2.6, 5.1) mIU\/mL. Comorbidities included diabetes (18%), hyperlipidemia (46%), hypertension (44%), prior radical prostatectomy (41%), prostate radiotherapy (12%), and ADT (4.5%). Treatment response was achieved in 136 of 292 (47%) patients; 156 (53%) failed to meet response criteria within 12-weeks. Multivariable analysis identified baseline LH (increase per mIU\/mL) (OR 0.82, CI = 0.71-0.95, P\u00a0=\u2009.008) as a significant negative predictor for achieving treatment response. Likewise, prior ADT was predictive for poor response (OR 0.11, CI = 0.01-0.6, P\u00a0=\u2009.039). Baseline TT and age at start of CC treatment were not predictive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>Identification of predictors for CC treatment response enables individualized counseling, leading to better informed treatment decisions and avoidance of treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>Strengths include cohort size, utilization of the gold-standard lab assessment for TT (LCMS), and standardized reproducible clinical pathways. Limitations include having a study population that is skewed older and less healthy than average, lack of long-term follow-up, and lack of quantifiable data on symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In men with low testosterone, this study found that higher baseline LH and history of prior ADT predicted worse response to CC therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag159","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:25:11Z","timestamp":1778585111000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictors of clomiphene citrate response in the treatment of men with testosterone deficiency"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8099-1168","authenticated-orcid":false,"given":"Daniel J","family":"Kim","sequence":"first","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Assel","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elshafei","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Liso","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Vickers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-3047","authenticated-orcid":false,"given":"John P","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-7037","authenticated-orcid":false,"given":"Jose M","family":"Flores","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"issue":"5","key":"2026060802383263700_ref1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jcem-29-5-638","article-title":"Clomiphene citrate: a correlation of its effect on sperm concentration and morphology, total gonadotropins, ICSH, estrogen and testosterone excretion, and testicular cytology in normal men","volume":"29","author":"Heller","year":"1969","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060802383263700_ref2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-5347(17)59072-2","article-title":"Clomiphene citrate in the management of male infertility","volume":"115","author":"Paulson","year":"1976","journal-title":"J Urol"},{"issue":"2","key":"2026060802383263700_ref3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.sxmr.2018.10.001","article-title":"Clomiphene citrate for the treatment of hypogonadism","volume":"7","author":"Wheeler","year":"2019","journal-title":"Sex Med Rev"},{"issue":"4","key":"2026060802383263700_ref4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1464-410X.2011.10702.x","article-title":"Outcomes of clomiphene citrate treatment in young hypogonadal men","volume":"110","author":"Katz","year":"2012","journal-title":"BJU Int"},{"issue":"10","key":"2026060802383263700_ref5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1464-410X.2012.10968.x","article-title":"Clomiphene citrate is safe and effective for long-term management of hypogonadism","volume":"110","author":"Moskovic","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"2026060802383263700_ref6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.juro.2014.03.089","article-title":"Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy","volume":"192","author":"Ramasamy","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"2026060802383263700_ref7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1743-6109.2009.01454.x","article-title":"Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost","volume":"7","author":"Taylor","year":"2010","journal-title":"J Sex Med"},{"issue":"3","key":"2026060802383263700_ref8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/humupd\/6.3.212","article-title":"A pharmacological review of selective oestrogen receptor modulators","volume":"6","author":"Goldstein","year":"2000","journal-title":"Hum Reprod Update"},{"key":"2026060802383263700_ref9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.urology.2020.04.074","article-title":"Baseline gonadotropin levels and testosterone response in hypogonadal men treated with clomiphene citrate","volume":"142","author":"Keihani","year":"2020","journal-title":"Urology."},{"issue":"9","key":"2026060802383263700_ref10","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1111\/jsm.12592","article-title":"Predicting biochemical response to clomiphene citrate in men with hypogonadism","volume":"11","author":"Mazzola","year":"2014","journal-title":"J Sex Med"},{"issue":"2","key":"2026060802383263700_ref11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"3","key":"2026060802383263700_ref12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of Urology guidelines on sexual and reproductive Health-2021 update: male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"2026060802383263700_ref13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/jsxmed\/qdad030","article-title":"Clomiphene citrate therapy for testosterone deficiency: a proposed clinical care pathway","volume":"20","author":"Flores","year":"2023","journal-title":"J Sex Med"},{"issue":"43","key":"2026060802383263700_ref14","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"issue":"1","key":"2026060802383263700_ref15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"issue":"2","key":"2026060802383263700_ref16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.21037\/tau.2020.01.30","article-title":"Pre-treatment estradiol does not predict testosterone response to clomiphene citrate","volume":"9","author":"Masterson","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"6","key":"2026060802383263700_ref17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1210\/jcem-33-6-970","article-title":"Short- and long-term effects of clomiphene citrate on the pituitary-testicular axis","volume":"33","author":"Santen","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060802383263700_ref18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.juro.2012.02.2021","article-title":"1499 Defining the rate of tachyphylaxis IN patients using daily clomiphene citrate","volume":"187","author":"Mazzola","year":"2012","journal-title":"J Urol"},{"issue":"4","key":"2026060802383263700_ref19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0022-5347(17)43497-5","article-title":"Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis","volume":"138","author":"Hadziselimovic","year":"1987","journal-title":"J Urol"},{"issue":"7","key":"2026060802383263700_ref20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jsxm.2016.04.068","article-title":"Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials","volume":"13","author":"Trost","year":"2016","journal-title":"J Sex Med"},{"issue":"6","key":"2026060802383263700_ref21","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.eururo.2007.05.021","article-title":"Relationship between the Saint Louis university ADAM questionnaire and sexual hormonal levels in a male outpatient population over 50 years of age","volume":"52","author":"Mart\u00ednez-Jabaloyas","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"2026060802383263700_ref22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.maturitas.2005.07.004","article-title":"Comparison of screening questionnaires for the diagnosis of hypogonadism","volume":"53","author":"Morley","year":"2006","journal-title":"Maturitas."}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag159\/68485178\/qdag159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag159\/68485178\/qdag159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:38:38Z","timestamp":1780900718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag159\/8703479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag159","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]},"article-number":"qdag159"}}